BNGO250117C500
- 0.05
- 0.000.00%
Bionano Genomics Newsroom
Bionano Announces Publication From Johns Hopkins School of Medicine Showing That OGM Outperformed Multiple Cytogenetic Assays in a Study of Bone and Soft Tissue Tumor Analysis
Bionano Announces the Publication of Stockholder Letter Regarding Support for Proxy Proposal
Bionano Genomics Announces Presentations at ASH Annual Meeting
Express News | Bionano Announces Presentations at the American Society of Hematology (Ash) Annual Meeting That Underscore Ogm Utility Across Blood Cancer Research and Cell & Gene Therapy
Hold Rating on BioNano Genomics Amid Revenue Shortfall and Strategic Shift
Bionano Genomics Analyst Ratings
Scotiabank Maintains Bionano Genomics(BNGO.US) With Hold Rating, Maintains Target Price $1
Scotiabank Sticks to Their Hold Rating for BioNano Genomics (BNGO)
Ladenburg Thalmann Downgrades Bionano Genomics(BNGO.US) to Hold Rating
Bionano Genomics Downgraded to Neutral From Buy at Ladenburg
10-Q: Q3 2024 Earnings Report
Bionano Genomics Sees Growth in OGM Adoption
Bionano Genomics, Inc. (BNGO) Q3 2024 Earnings Call Transcript Summary
Bionano Genomics, Inc. (BNGO) Q3 2024 Earnings Call Transcript
Earnings Snapshot: Bionano Genomics Misses Topline Estimate in Q3
Bionano Genomics Reports Q3 Revenue $6.1M, Consensus $7.85M.
8-K: Bionano Reports Third Quarter 2024 Results and Highlights Recent Business Progress
Express News | Bionano Genomics Drops 5.3% After the Bell Following Results
Bionano Genomics 3Q Loss $44.2M >BNGO
Express News | Bionano Genomics Q3 Revenue USD 6.1 Million Vs. IBES Estimate USD 7.85 Million